Application of GPRC5D targeting therapy in relapsed refractory multiple myeloma

Targeted therapies are significantly advancing the treatment of multiple myeloma (MM). While BCMA-targeted therapies have shown success, GPRC5D is a promising emerging target for relapsed/refractory MM (RRMM). Ongoing research and clinical trials suggest GPRC5D-targeted therapy could be a significant breakthrough in MM treatment. Further studies are needed to evaluate optimal treatment combinations.